ArticleThe World Allergy Organization journal2026
Short-term high-dose budesonide nasal spray for postoperative uncontrolled chronic rhinosinusitis: A randomized controlled trial.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The goal of treatments for chronic rhinosinusitis (CRS) is to achieve and maintain clinical control. However, more than 40% of patients showed uncontrolled disease after endoscopic sinus surgery (ESS). To date, research guidance on optimal dosing regimens for intranasal corticosteroid spray (INCS) in uncontrolled CRS remains limited. Methods: This prospective, randomized controlled trial enrolled 43 patients with uncontrolled CRS ≥6 months post-ESS. Participants received either high-dose (1024 μg/day) or control-dose (256 μg/day) budesonide nasal spray for 14 days in a non-blinded manner. Outcomes included symptom scores (TNSS, VAS), quality of life (SNOT-22), endoscopic findings. We also explored the subgroup analyses by comparing eosinophilic (ECRS) and non-eosinophilic CRS (NECRS). Intention-to-treat (ITT) analysis was used in this clinical trial. Results: The study recruited 43 patients (high-dose group = 21, control group = 22).The high-dose group exhibited significantly greater reductions in TNSS, endoscopic E score, and Lund-Kennedy score (P < 0.05), and improved nasal obstruction VAS (P = 0.027). Subgroup analysis revealed superior efficacy in ECRS patients (endoscopic score reduction: P < 0.05). Adverse events were mild and comparable between groups (high-dose group 2/21 [9.5%] vs. Control group 1/22 [4.5%], P > 0.05). Conclusions: Short-term high-dose budesonide nasal spray is effective and safe for postoperative uncontrolled CRS, particularly in ECRS, offering a rapid therapeutic alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.